Statistics for Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events
Total visits
| views | |
|---|---|
| Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events | 2 |
Total visits per month
| views | |
|---|---|
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
File Visits
| views | |
|---|---|
| nihms-1774268.pdf | 10 |
Top country views
| views | |
|---|---|
| United States | 2 |
Top city views
| views | |
|---|---|
| Franklin | 2 |